- Prescriptions for semaglutide, marketed under the names Ozempic and Wegovy, surged almost 3,000% in the U.S. from 2018 to 2022.
- Encounters of gallbladder inflammation in California hospitals surged by 492% during the study period, potentially linked to the slowed digestion caused by long-term semaglutide use.
- Hospital encounters in California related to acute kidney injuries rose by 18% and cases of low blood sugar (hypoglycemia) increased by 27%, suggesting these may be emerging areas of concern for semaglutide users.
Read the complete article that reviews the changes in semaglutide side effect prevalences in California hospitals associated with increased use of Ozempic and Wegovy: here.
